Green Cross LabCell Obtains Patent Rights for Composition Related to GM1 Gangliosidosis Treatment
[Asia Economy Reporter Kum Boryeong] Green Cross LabCell announced on the 21st that it has acquired a patent related to 'a novel drug delivery composition and a pharmaceutical composition for treating GM1 gangliosidosis containing it as an active ingredient.'
Hot Picks Today
![About 100 Trillion Won at Stake... "Samsung Strike Is an Unprecedented Opportunity" as Prices Surge 20% [Taiwan Chip Column]](https://cwcontent.asiae.co.kr/asiaresize/93/2026051416263163580_1778743590.jpg)
About 100 Trillion Won at Stake... "Samsung Strike Is an Unprecedented Opportunity" as Prices Surge 20% [Taiwan Chip Column]
- "Heading for 2 Million Won": The Company the Securities Industry Says Not to Doubt [Weekend Money]
- "Envious of Korean Daily Life"...Foreign Tourists Line Up in Central Myeongdong from Early Morning [Reportage]
- "Anyone Who Visited the Room Salon, Come Forward"… Gangnam Police Station Launches Full Staff Investigation After New Scandal
- Did Samsung and SK hynix Rise Too Much?... Foreign Assets Grow Despite Selling [Weekend Money]
Green Cross LabCell stated, "The nucleic acid drug delivery composition according to this invention presents a new drug delivery system technology that can solve the problem of low efficiency of drugs reaching the brain nervous system due to the blood-brain barrier in central nervous system diseases," adding, "This technology enables non-invasive delivery of nucleic acid drugs to the brain nervous system and can be widely applied to various central nervous system diseases."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
